How do toxic proteins accumulate in Alzheimer’s and other diseases? (Links to an external site)

Stress granules (red) fill stem cell-derived neurons (nuclei shown in blue) from a person with a mutation in the tau gene. Researchers at Washington University School of Medicine in St. Louis have figured out the connection between tau mutations and stress granules, a discovery which could potentially lead to new approaches to treating a group of neurodegenerative diseases known as tauopathies.

Under normal circumstances, tau protein is part of the brain’s infrastructure, important for stabilizing neurons into their proper shapes. But sometimes tau gets knotted up into tangles and turns toxic, injuring brain tissue and causing tauopathies, a group of brain diseases characterized by problems with learning, memory and movement. Alzheimer’s disease is the most common […]

Understanding the Varying Uses of Thrombolysis in Pediatric Stroke Settings: Kristin Guilliams, MD, MSCI (Links to an external site)

Kristin Guilliams on NeurologyLive

Ischemic stroke in the pediatric population is rare; however, stroke in children in the acute setting can be missed because of its low prevalence. Care for acute pediatric strokes involves determining the most likely etiology in a timely manner, understanding available resources, and making the best choice based on the information at hand, according to […]

Blood-based biomarkers for treatment monitoring in Alzheimer’s disease (Links to an external site)

Suzanne Schindler

Suzanne Schindler, MD, PhD, Washington University in St. Louis School of Medicine, St. Louis, MO, discusses the promise of blood-based biomarkers for treatment monitoring. Data has been presented on plasma phosphorylated-tau 217 (p-tau217) as a method to monitor the effects of lecanemab and donanemab. This research is investigating if medication discontinuation is feasible if p-tau217 […]

What to know about the new Alzheimer’s drug Leqembi (Links to an external site)

The FDA has granted full approval to Leqembi (lecanemab) for patients in the early stages of Alzheimer’s disease. WashU Medicine will offer the drug to those eligible for it, in collaboration with BJC HealthCare.

The Food and Drug Administration (FDA) recently gave full approval to Leqembi (lecanemab) for patients in the early stages of Alzheimer’s disease. Physicians and researchers at Washington University School of Medicine’s Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC) in St. Louis were involved in the clinical trials evaluating Leqembi, in which they enrolled […]

St. Louis has highest Alzheimer’s rate in Missouri, with more than 1 in 10 adults affected (Links to an external site)

The city of St. Louis has the highest rate of Alzheimer’s dementia cases in Missouri, and new evidence from Washington University’s School of Medicine shows that social factors like income, race and education play a role in access to treatment and diagnosis. The new observational study, focused on the Washington University Memory Diagnostic Center, showed […]

Cognitive function in Down syndrome-associated Alzheimer’s focus of grant (Links to an external site)

Neurologist Beau Ances, MD, PhD, talks with his patient, Adam Kloppenberg, who has Down syndrome, at Washington University School of Medicine in St. Louis. People with Down syndrome are at very high risk of developing Alzheimer’s disease. Ances is involved in a project led by Jason Hassenstab, PhD, an associate professor of neurology, to develop tools to measure cognitive function in people with Down syndrome-associated Alzheimer’s disease.

Nearly every person with Down syndrome eventually develops Alzheimer’s disease, yet people with the syndrome routinely are excluded from Alzheimer’s clinical trials, as the cognitive assessment tools designed for the general population often are inappropriate for people with developmental disabilities. Consequently, nobody knows whether the new Alzheimer’s therapeutics hitting the market will work for people […]

Study defines disparities in memory care (Links to an external site)

Members of minoritized racial or ethnic groups and people who live in less affluent neighborhoods are less likely than others to receive specialized care for dementia, including Alzheimer’s disease, a new study from Washington University School of Medicine in St. Louis indicates.

Patients who live in less affluent neighborhoods and those from underrepresented racial or ethnic groups are less likely than others to receive specialized care for dementia, including Alzheimer’s disease, a new study from Washington University School of Medicine in St. Louis indicates. Further, the research shows that Black people are more likely than white people […]

Cynthia Hodge announced as Department of Neurology’s Staff Employee of the Quarter

Cindy Hodge

The Department of Neurology congratulates former Neurology Research Lab Manager Cynthia Hodge for being awarded the Neurology Staff Employee of the Quarter for Q4 FY23. Hodge was nominated by faculty and staff because of her hard work and dedication to her role and the people she manages. Those who nominated her, in particular, highlighted how […]

Tau-based biomarker tracks Alzheimer’s progression (Links to an external site)

Kanta Horie, PhD, works with a mass spectrometer that he uses to measure protein levels in cerebrospinal fluid samples. Horie and colleagues at Washington University School of Medicine in St. Louis and Lund University in Sweden have discovered that a form of the protein tau in the cerebrospinal fluid known as MTBR-tau243 can be used to track the progression of Alzheimer's disease and could speed drug development.

Two pathologies drive the progression of Alzheimer’s disease. Early on, amyloid beta plaques lead the way, but around the time cognitive symptoms arise, tau tangles take over as the driving force and cognition steadily declines. Tracking the course of the disease in individual patients has been challenging because there’s been no easy way to measure […]

There’s Now a Rapid, Accurate COVID-19 Air Detector (Links to an external site)

fStop—Getty Images

The COVID-19 pandemic will forever be associated with unprecedented lockdowns and inconveniences such as wearing masks in public. And that’s largely because health experts had no idea exactly where the SARS-CoV-2 virus was lurking, and how risky crowded settings such as workplaces, classrooms, and public transportation were.